Kala Pharmaceuticals Inc (KALA)

3.120
+0.050(+1.63%)
After Hours
3.090
-0.030(-0.962%)
- Real-time Data
  • Volume:
    1,916,339
  • Bid/Ask:
    2.980/3.140
  • Day's Range:
    2.940 - 3.120

KALA Overview

Prev. Close
3.07
Day's Range
2.94-3.12
Revenue
10.78M
Open
3.07
52 wk Range
2.67-9.91
EPS
-2.1
Volume
1,916,339
Market Cap
202.71M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,491,926
P/E Ratio
-
Beta
0.41
1-Year Change
-64.34%
Shares Outstanding
64,971,096
Next Earnings Date
Nov 11, 2021
What is your sentiment on Kala Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Kala Pharmaceuticals Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyNeutralSellStrong Sell
Technical IndicatorsBuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyBuyStrong SellStrong Sell

Kala Pharmaceuticals Inc Company Profile

Kala Pharmaceuticals Inc Company Profile

Employees
188

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company’s product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Read More
  • What are the thoughts of the Lord? where is the bottom. Will it be 14 again and when
    0
    • I do not know how to escape ( average 9 and 1000 shares ((
      0
      • You shoukd not escape give it some time will be 15 plus ! 5/6 monthes
        0
      • If you have cash available to trade buy moreCost per share will reduce easy to sell with profitWaiting gameGood luck this stock will soar soon when market trend upwards
        0
    • no new comments?
      0
      • why sell off?
        0
        • I have no clue
          0
      • Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
        0
        • FDA approves topical corticosteroid for treatment of dry eye disease
          0
          • FDA approves topical corticosteroid for treatment of dry eye disease
            0
            • right on time...
              0
              • right on time...
                0
                • It’s going to touch the bottom 4$/share and like last year I see trend reversal around end of Dec 2019. Those who bought this year will have to wait next year to sell...
                  1
                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.